FDA schedules March ODAC for Geron’s MDS drug following PhIII data

Bay Area biotech Geron’s stock dipped slightly Monday after the FDA announced an Oncologic Drugs Advisory Committee for the company’s experimental drug imetelstat.

Imetelstat is an injectable drug designed to treat adult patients with anemia who are dependent on transfusions, and who also have myelodysplastic syndromes (MDS). The company has…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks